Microbiome metabolites associated with worse outcomes on immunotherapy in RCC pts. Thrilled to welcome Shahla Bari MD to DCI Center for Prostate & Urologic Cancers. Thanks Prostate Cancer Foundation for her #YoungInvestigatorAward

We celebrate the beginning of the ASCO presidency of Dr Lynn Schuchter Robin Zon, MD, FACP, FASCO, inspired by her visionary theme "The Art and Science of Cancer Care: From Comfort to Cure." As #ASCO23 ends tomorrow we're already planning #ASCO24. I can't wait to see your vision come together!

Going away party for our great friend and colleague Dr Brant Inman who is departing Duke Urology Duke Cancer DCI Center for Prostate & Urologic Cancers and returning to Canada. We wish him well but he will be so hard to replace - amazing surgeon and brilliant researcher Dan George Andrew Armstrong

Congrats Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO!

#DYK that #TesticularCancer is the most common cancer type found in men between the ages of 15 and 34? 🤔 #MensHealthWeek Learn more about the facts and how you can be screened here: cancer.gov/types/testicul…

A new era begins ⁦Duke Health⁩ ⁦Duke University School of Medicine⁩ ⁦Duke Urology⁩ First surgery as the Department of Urology. ⁦⁦Duke Urology Residency Program⁩ ⁦Duke Pediatric Urology⁩

New table of IO doublets in sarcomatoid RCC: 1. Central path review done for ipi/nivo while other datasets relied on local path report 2. IO/VEGF with very short f/u and thus wide CIs 3. Ipi/nivo notable for high CR rate and high landmarks with long f/u 4. No detailed CLEAR data

A #pulmonaryfibrosis patient rode his bicycle on a 2-day trip from Virginia to demonstrate his recovery from a #lungtransplant on his one-year check-up. DukeCTSurgery | Duke Surgery | Duke Heart | #LungTransplant | #PulmonaryFibrosis

This #OpenAccess review summarizes key topics discussed to advance research on the role of energy balance, including physical activity, body composition, and dietary intake, on cancer development, cancer outcomes, and healthy survivorship. 🔗 acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

Very excited to share with you incredibly promising data for #zanzalintinib (#XL092) in patients with #kidneycancer. A million thanks to Kidney Cancer for allowing us to present this data in a highlighted oral session at #IKCSNA23! See my slides/thoughts here: (1/9)

Awesome to present on favorable risk mRCC at #worldgu24 with such luminaries as Tian Zhang, MD, MHS Eric Jonasch Rana McKay, MD, FASCO & Dan George! Goals of care (GOC) discussions are particularly important in this group of pts who have multiple options (including no treatment at all).

A view from the stage during the hilarious & enlightening IO-IO vs IO-TKI debate between Rana McKay, MD, FASCO & #DavidMcDermott.

Can’t wait to see the movie of his amazing story! John O'Leary Tian Zhang, MD, MHS World GU Conference

Important data by Dan George, Hannah Dzimitrowicz McManus & colleagues from IRONMAN Registry showing how generalizable mHSPS combo therapy data is to real world practice! Kudos to World GU Conference for elevating the voices of emerging stars in the field.

Ready for day 2 (bladder cancer) of #WorldGU24! World GU Conference What will the opening ceremony be?

Singing and dancing by the Rat Pack & Rockettes to open the day (New York, New York!) and introduce “the real chairman of the board” Dan George!

Despite being negative, CONTACT-03 is one of the most important studies in mRCC. With negative TiNivo-2, while disappointing, both give us confidence to DC PD-1 after progression & avoid tox. Brian Rini, MD Tom Powles Uromigos World GU Conference #WorldGU24

I appreciate Uromigos getting down to brass tacks as to how trial data affects day to day clinical GU practice! Great insights from community oncology colleagues. World GU Conference #WorldGU24

I would happily wear this t-shirt! Dr Kathryn Schmitz